NO20051170L - Terapeutiske kombinasjoner av erb-B-kinase inhibitorer og anti-neoplastiske terapier - Google Patents
Terapeutiske kombinasjoner av erb-B-kinase inhibitorer og anti-neoplastiske terapierInfo
- Publication number
- NO20051170L NO20051170L NO20051170A NO20051170A NO20051170L NO 20051170 L NO20051170 L NO 20051170L NO 20051170 A NO20051170 A NO 20051170A NO 20051170 A NO20051170 A NO 20051170A NO 20051170 L NO20051170 L NO 20051170L
- Authority
- NO
- Norway
- Prior art keywords
- erb
- kinase inhibitors
- therapeutic combinations
- neoplastic therapies
- neoplastic
- Prior art date
Links
- 230000000118 anti-neoplastic effect Effects 0.000 title 1
- 229940034982 antineoplastic agent Drugs 0.000 title 1
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000005865 ionizing radiation Effects 0.000 abstract 1
- 230000002427 irreversible effect Effects 0.000 abstract 1
- 229960003552 other antineoplastic agent in atc Drugs 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 abstract 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 abstract 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40170502P | 2002-08-07 | 2002-08-07 | |
| US46224703P | 2003-04-11 | 2003-04-11 | |
| PCT/IB2003/003388 WO2004014386A1 (en) | 2002-08-07 | 2003-07-28 | Therapeutic combinations of erb b kinase inhibitors and antineoplastic therapies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20051170L true NO20051170L (no) | 2005-05-06 |
Family
ID=31720553
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20051170A NO20051170L (no) | 2002-08-07 | 2005-03-04 | Terapeutiske kombinasjoner av erb-B-kinase inhibitorer og anti-neoplastiske terapier |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20040067942A1 (https=) |
| EP (1) | EP1549320A1 (https=) |
| JP (1) | JP2005538129A (https=) |
| CN (1) | CN1674908A (https=) |
| AR (1) | AR040792A1 (https=) |
| AU (1) | AU2003249450A1 (https=) |
| BR (1) | BR0313470A (https=) |
| CA (1) | CA2494270A1 (https=) |
| IL (1) | IL166423A0 (https=) |
| MX (1) | MXPA05001430A (https=) |
| NO (1) | NO20051170L (https=) |
| PA (1) | PA8578001A1 (https=) |
| PE (1) | PE20040990A1 (https=) |
| PL (1) | PL375414A1 (https=) |
| RU (1) | RU2005102836A (https=) |
| TW (1) | TW200404532A (https=) |
| WO (1) | WO2004014386A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7951780B2 (en) * | 2004-02-25 | 2011-05-31 | Astellas Pharma Inc. | Antitumor agent |
| US7695731B2 (en) * | 2004-03-22 | 2010-04-13 | Cordis Corporation | Local vascular delivery of etoposide in combination with rapamycin to prevent restenosis following vascular injury |
| RU2413731C2 (ru) | 2004-04-09 | 2011-03-10 | Чугаи Сейяку Кабусики Кайся | Новые растворимые в воде пролекарства |
| CN1972688B (zh) | 2004-05-06 | 2012-06-27 | 沃尼尔·朗伯有限责任公司 | 4-苯胺基-喹唑啉-6-基-酰胺类化合物 |
| BRPI0510657A (pt) | 2004-06-03 | 2007-12-04 | Hoffmann La Roche | tratamento com cisplatina e com um inibidor de egfr |
| EP1755608A1 (en) * | 2004-06-03 | 2007-02-28 | F.Hoffmann-La Roche Ag | Treatment with gemcitabine and an egfr-inhibitor |
| WO2005117877A1 (en) * | 2004-06-03 | 2005-12-15 | F.Hoffmann-La Roche Ag | Treatment with irinotecan (cpt-11) and an egfr-inhibitor |
| CA2569139A1 (en) * | 2004-06-04 | 2005-12-22 | Smithkline Beecham (Cork) Limited | Lapatinib with letrozole for use in a treatment of breast cancer |
| TW200744603A (en) * | 2005-08-22 | 2007-12-16 | Chugai Pharmaceutical Co Ltd | Novel anticancer concomitant drug |
| US20080045589A1 (en) * | 2006-05-26 | 2008-02-21 | Susan Kelley | Drug Combinations with Substituted Diaryl Ureas for the Treatment of Cancer |
| RU2325199C2 (ru) * | 2006-06-20 | 2008-05-27 | Государственное учреждение научно-исследовательский институт онкологии Томского Научного центра Сибирского отделения Российской академии медицинских наук (ГУ НИИ онкологии ТНЦ СО РАМН) | Способ комбинированного лечения местно-распространенных форм рака шейки матки |
| US8168662B1 (en) | 2006-11-06 | 2012-05-01 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| US8173686B2 (en) | 2006-11-06 | 2012-05-08 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| US8168661B2 (en) | 2006-11-06 | 2012-05-01 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| US8178564B2 (en) | 2006-11-06 | 2012-05-15 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| AR064106A1 (es) * | 2006-12-05 | 2009-03-11 | Bayer Schering Pharma Ag | Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis |
| CN103169973A (zh) * | 2007-11-12 | 2013-06-26 | 彼帕科学公司 | 使用4-碘-3-硝基苯甲酰胺化合物与抗肿瘤剂组合治疗乳腺癌 |
| CN103596592A (zh) * | 2011-05-06 | 2014-02-19 | 梅里麦克制药股份有限公司 | 用于预防包含抗ErbB3试剂的联合治疗中的毒性药物间相互作用的方法 |
| WO2021178789A1 (en) * | 2020-03-06 | 2021-09-10 | Deciphera Pharmaceuticals, Llc | Methods of using rebastinib in the treatment of different cancerous disorders |
| CN118576599A (zh) * | 2020-10-23 | 2024-09-03 | 和记黄埔医药（上海）有限公司 | 一种药物组合产品在制备用于治疗非小细胞肺癌的药物中的用途 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6287223B1 (en) * | 1997-04-11 | 2001-09-11 | Liechty, Ii Victor Jay | Dulling prevention for sharp cutting edge of blade-opening arrowhead blades when in a closed in-flight position |
| US6147107A (en) * | 1998-12-20 | 2000-11-14 | Virginia Commonwealth University | Specific inhibition of the P42/44 mitogen activated protein (map) kinase cascade sensitizes tumor cells |
| US6281223B1 (en) * | 1999-04-13 | 2001-08-28 | Supergen, Inc. | Radioenhanced camptothecin derivative cancer treatments |
| WO2002055106A2 (en) * | 2001-01-09 | 2002-07-18 | Merck Patent Gmbh | Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors |
-
2003
- 2003-07-22 PA PA20038578001A patent/PA8578001A1/es unknown
- 2003-07-28 BR BR0313470-9A patent/BR0313470A/pt not_active IP Right Cessation
- 2003-07-28 RU RU2005102836/14A patent/RU2005102836A/ru not_active Application Discontinuation
- 2003-07-28 PL PL03375414A patent/PL375414A1/xx not_active Application Discontinuation
- 2003-07-28 CA CA002494270A patent/CA2494270A1/en not_active Abandoned
- 2003-07-28 AU AU2003249450A patent/AU2003249450A1/en not_active Abandoned
- 2003-07-28 WO PCT/IB2003/003388 patent/WO2004014386A1/en not_active Ceased
- 2003-07-28 CN CNA038191180A patent/CN1674908A/zh active Pending
- 2003-07-28 EP EP03784371A patent/EP1549320A1/en not_active Withdrawn
- 2003-07-28 MX MXPA05001430A patent/MXPA05001430A/es unknown
- 2003-07-28 JP JP2004527183A patent/JP2005538129A/ja not_active Withdrawn
- 2003-07-28 IL IL16642303A patent/IL166423A0/xx unknown
- 2003-08-01 US US10/632,281 patent/US20040067942A1/en not_active Abandoned
- 2003-08-04 PE PE2003000768A patent/PE20040990A1/es not_active Application Discontinuation
- 2003-08-05 AR AR20030102806A patent/AR040792A1/es unknown
- 2003-08-06 TW TW092121515A patent/TW200404532A/zh unknown
-
2005
- 2005-03-04 NO NO20051170A patent/NO20051170L/no unknown
-
2006
- 2006-08-14 US US11/464,249 patent/US20060293323A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BR0313470A (pt) | 2005-06-21 |
| EP1549320A1 (en) | 2005-07-06 |
| CN1674908A (zh) | 2005-09-28 |
| PE20040990A1 (es) | 2004-12-27 |
| PA8578001A1 (es) | 2004-05-07 |
| WO2004014386A1 (en) | 2004-02-19 |
| TW200404532A (en) | 2004-04-01 |
| JP2005538129A (ja) | 2005-12-15 |
| MXPA05001430A (es) | 2005-06-06 |
| AR040792A1 (es) | 2005-04-20 |
| US20040067942A1 (en) | 2004-04-08 |
| US20060293323A1 (en) | 2006-12-28 |
| IL166423A0 (en) | 2006-01-15 |
| RU2005102836A (ru) | 2005-08-10 |
| PL375414A1 (en) | 2005-11-28 |
| CA2494270A1 (en) | 2004-02-19 |
| AU2003249450A1 (en) | 2004-02-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20051170L (no) | Terapeutiske kombinasjoner av erb-B-kinase inhibitorer og anti-neoplastiske terapier | |
| BR112023012301A2 (pt) | Combinações farmacêuticas que compreendem um inibidor de kras g12c e usos de um inibidor de kras g12c para o tratamento de cânceres | |
| CL2023003965A1 (es) | Inhibidores cdk2. | |
| BR112021023825A2 (pt) | Inibidores heterobicíclicos de mat2a e métodos de uso para tratamento de câncer | |
| AR045268A1 (es) | Procedimiento para tratar la sobreexpresion del receptor erbb2 en un mamifero que necesite dicho tratamiento | |
| NO20053775L (no) | Diazepinoindol derivater som kinaseinhibitorer. | |
| NO20066056L (no) | Behandling med Gemcitabin og en EGFR-inhibitor | |
| BR0308854A (pt) | Benzazolas substituìdas e seus usos como inibidoras de quinase raf | |
| BRPI0617165A2 (pt) | Compostos inibidores mek, composições farmacêuticas que os contem e métodos de uso dos mesmos | |
| TW200501960A (en) | Synergistic kits and compositions for treating cancer | |
| NO20082907L (no) | Fremgangsmate for anvendelse av IL6 antagonister med proteasom-inhibitorer | |
| NO20041598L (no) | Fremgangsmater for behandling eller profylakse av vaskulaer betennelse ved anvendelse av sterolabsorpsjonsinhibitor(er) | |
| NO20052888L (no) | Diamintriazoler anvendelige som inhibitorer av proteinkinaser | |
| BR0116575A (pt) | Terapia combinada que usa inibidores de tirosina cinase receptora e inibidores de angiogênese | |
| CY1111374T1 (el) | Ενωσεις που περιεχουν στροντιο για χρηση στην προληψη ή θεραπεια παθησεων νεκρωτικων οστων | |
| MX2024004216A (es) | Terapias combinadas de inhibidores de kras g12d con inhibidores de la familia pan erbb. | |
| NO20051539L (no) | N-biarylmetylaminosykloalkankarboksamidderivater | |
| PY2261702A (es) | Compuestos y composiciones para el tratamiento de enfermedades relacionadas con el coronavirus | |
| JOP20250150A1 (ar) | علاجات السرطان باستخدام مثبطات prmt5 التعاونية مع mta | |
| CO2022000266A2 (es) | Inhibidores de enzimas | |
| CO2023012342A2 (es) | Inhibidores de enzimas | |
| MX2024006934A (es) | Tratamiento del cancer con un inhibidor de la cinasa fgfr | |
| MXPA03000089A (es) | Uso de inhibidores de cinasa de tirosina de proteina de egf-r para prevenir el fotoenvejecimiento de la piel humana. | |
| AR039986A1 (es) | Metodo para reducir el dolor usando virus oncoliticos | |
| MX2025001050A (es) | Terapia de combinacion de inhibidores de la cinasa dependiente de ciclina 7 (cdk7) con otras terapias anticancer |